This is great news in terms of seeing continued R&D advancements from Illumina, but I question their ability to independently tackle the diagnostics market. They've made very little progress over the past several years. Until it becomes a priority, I don't see anything changing.
Illumina will remain an independent company, at least for now. The San Diego-based company (NASDAQ: ]), the market leading maker of DNA sequencing
Add a comment...